(Q43285200)

18 November 2017

title

The as-yet unfulfilled promise of p38 MAPK inhibitors (English)

1 reference

18 November 2017

Susan E Sweeney

1

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Nature Reviews Rheumatology

18 November 2017

published in

1 reference

18 November 2017

volume

5

1 reference

18 November 2017

issue

9

1 reference

18 November 2017

page(s)

475-477

1 reference

The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Inhibition of p38: has the fat lady sung?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Regulation of peripheral inflammation by spinal p38 MAP kinase in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Rheumatoid arthritis in a mouse?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.171

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19710669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Is spleen tyrosine kinase inhibition an effective therapy for patients with RA?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19710669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2009.171

1 reference

18 November 2017

1 reference